Skip to main content
. 2021 Apr 23;13(9):2049. doi: 10.3390/cancers13092049

Figure 4.

Figure 4

Circulating blood components in patients with late stage non-small cell lung carcinoma. Several components can be isolated at diagnosis (baseline), including circulating free-DNA, circulating tumor cells, microRNA, platelets, and extracellular vesicles (mainly exosomes) for biomarker assessment. The majority of next-generation sequencing technologies are currently being developed from circulating free-DNA and from nucleic acids extracted from circulating tumor cells (green circles).